Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACI-15916 · 1 trial · 3 indications
Vital signs measurements will be performed after the PET scan is completed and will be compared with measurements performed before the injection of \[18F\]ACI-15916
\[18F\]ACI-15916 uptake in relevant regions of interest of the brain will be measured with PET scan and the mean of each group (participants with α-synucleinopathies and healthy volunteers) will be calculated
| Arm | Type | Description |
|---|---|---|
| Participants with suspected α-synucleinopathies | EXPERIMENTAL | The study population will be composed of participants with suspected α-synucleinopathies |
| Healthy volunteers | ACTIVE_COMPARATOR | The study population will be composed of healthy volunteers |
| Name | Type | Description |
|---|---|---|
| [18F]ACI-15916 | OTHER | \[18F\]ACI-15916 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits. |
Inclusion Criteria for all Participants: 1. Subject is able to provide written informed consent, which must be obtained before any assessment is performed. 2. Subjects must be able to understand and be willing to comply with study procedures, restrictions, and requirements. 3. Body mass index is \>...
ACI-15916 is an investigational diagnostic agent being studied for use in Parkinson's Disease (PD), as well as in related conditions including Multiple System Atrophy (MSA) and Dementia With Lewy Bodies (DLB). It is currently in early Phase 1 clinical development for these α-synucleinopathies.
ACI-15916 is a positron emission tomography (PET) imaging agent designed to target α-synuclein, the protein that accumulates in Parkinson's Disease and other α-synucleinopathies. It is being developed to enable visualization of α-synuclein pathology in the brain.
ACI-15916 is being developed by AC Immune SA, a biopharmaceutical company traded on NASDAQ under the ticker ACIU. The company is conducting clinical research on this agent for imaging α-synuclein in neurological conditions.
ACI-15916 is in early Phase 1 clinical development. It is an investigational agent and has not been approved by regulatory authorities. The ongoing trial is in the recruiting stage, with an enrollment target of 46 participants.
ACI-15916 is being studied in a single early Phase 1 clinical trial registered as NCT06891703, titled "[18F]ACI-15916 PET in α-synucleinopathies." This actively recruiting study is being conducted in Sweden and includes healthy volunteers as well as patients with Parkinson's Disease, Multiple System Atrophy, and Dementia With Lewy Bodies.
Yes, ACI-15916 is also known as [18F]ACI-15916, which refers to the radiolabeled form of the compound used in positron emission tomography (PET) imaging. The clinical trial NCT06891703 specifically evaluates [18F]ACI-15916 as a PET tracer for α-synucleinopathies.